Value-Based Care and Access Equity: How the Field Must Evolve to Keep Pace With Myeloma Innovation

In this episode, 'Value-Based Care and Access Equity: How the Field Must Evolve to Keep Pace With Myeloma Innovation,' the panelists explore the following question:

1. How do you think the field needs to evolve in terms of value-based care, cost-effectiveness frameworks, and access equity to keep pace with therapeutic innovation?

The panelists examined the growing tension between the pace of therapeutic innovation in multiple myeloma and the sustainability of its costs, noting that new drug approvals tend to carry a higher price tag than predecessors, even when comparative data does not demonstrate meaningful superiority, creating pressure on institutions to engage in repeated contracting negotiations and formulary stewardship discussions to ensure cost-effective access without compromising clinical quality. The discussion also explored the complexity of value-based decision-making at major referral centers, where enterprise-wide formulary decisions must simultaneously account for a broad payer mix, illustrating that there is no single framework that cleanly resolves the tension between innovation, access, and affordability.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the final episode, 'The Future of Multiple Myeloma: Pipeline Developments, Personalized Medicine, and Closing Thoughts,' panelists will share their final reflections on the multiple myeloma treatment landscape.